心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2017 ACC专家共识：非瓣膜性房颤患者围术期抗凝治疗的决策路径

2017-01-09 美国心脏病学会 JACC.2017.

非瓣膜性房颤患者围术期抗凝治疗

2017年1月，美国心脏病学会(ACC)发布了非瓣膜性房颤患者围术期抗凝治疗的决策路径专家共识。

中文标题：

2017 ACC专家共识：非瓣膜性房颤患者围术期抗凝治疗的决策路径

英文标题：

2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation

发布机构：

美国心脏病学会

发布日期：

2017-01-09

简要介绍：

2017年1月，美国心脏病学会(ACC)发布了非瓣膜性房颤患者围术期抗凝治疗的决策路径专家共识。

相关资料下载：
[AttachmentFileName(sort=100, fileName=2017 ACC专家共识：非瓣膜性房颤患者围术期抗凝治疗的决策路径)] GetToolGuiderByIdResponse(projectId=1, id=3fbc01c0013a8e64, title=2017 ACC专家共识：非瓣膜性房颤患者围术期抗凝治疗的决策路径, enTitle=2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation, guiderFrom=JACC.2017., authorId=null, author=, summary=2017年1月，美国心脏病学会(ACC)发布了非瓣膜性房颤患者围术期抗凝治疗的决策路径专家共识。, cover=, journalId=null, articlesId=null, associationId=849, associationName=美国心脏病学会, associationIntro=null, copyright=0, guiderPublishedTime=Mon Jan 09 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=2017年1月，美国心脏病学会(ACC)发布了非瓣膜性房颤患者围术期抗凝治疗的决策路径专家共识。<div><br><div> 拓展指南：<strong>与<font color="red">非瓣膜性房颤</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=3fbc01c0013a8e64" title="2017 ACC专家共识：非瓣膜性房颤患者围术期抗凝治疗的决策路径" target="_blank">2017 ACC专家共识：非瓣膜性房颤患者围术期抗凝治疗的决策路径</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=60d7d1c00130698d" title="2015 NICE技术评估指南：依度沙班预防非瓣膜性房颤患者卒中和全身性栓塞（TA355）" target="_blank">2015 NICE技术评估指南：依度沙班预防非瓣膜性房颤患者卒中和全身性栓塞（TA355）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=bf8961c001232a5c" title="2016 EHRA实用指南：应用非维生素K拮抗剂类口服抗凝剂治疗非瓣膜性房颤患者（更新）" target="_blank">2016 EHRA实用指南：应用非维生素K拮抗剂类口服抗凝剂治疗非瓣膜性房颤患者（更新）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=574b61c0012292a2" title="2015 EHRA实用指南：应用非维生素K拮抗剂类口服抗凝剂治疗非瓣膜性房颤患者（更新）" target="_blank">2015 EHRA实用指南：应用非维生素K拮抗剂类口服抗凝剂治疗非瓣膜性房颤患者（更新）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=c40331c0011a3204" title="2014 韩国心律学会声明：非瓣膜性房颤患者的抗血栓治疗" target="_blank">2014 韩国心律学会声明：非瓣膜性房颤患者的抗血栓治疗</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E9%9D%9E%E7%93%A3%E8%86%9C%E6%80%A7%E6%88%BF%E9%A2%A4" target="_blank">有关非瓣膜性房颤更多指南</a></ul></div></div>, tagList=[TagDto(tagId=45249, tagName=非瓣膜性房颤患者围术期抗凝治疗)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=1, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6759, appHits=472, showAppHits=0, pcHits=5365, showPcHits=1543, likes=182, shares=8, comments=8, approvalStatus=1, publishedTime=Tue Jan 10 18:37:02 CST 2017, publishedTimeString=2017-01-09, pcVisible=1, appVisible=1, editorId=5295957, editor=lili, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=lili, createdTime=Tue Jan 10 18:37:02 CST 2017, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 11:02:01 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2017 ACC专家共识：非瓣膜性房颤患者围术期抗凝治疗的决策路径)])
2017 ACC专家共识：非瓣膜性房颤患者围术期抗凝治疗的决策路径
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=170542, encodeId=ebeb1e0542d1, content=学习啦，谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/31/60fc0213ae09a3dbbba19993663ef4db.jpg, createdBy=33c31971480, createdName=1e160a78m83(暂无匿称), createdTime=Sun Jan 15 16:06:32 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=169936, encodeId=248e1699364a, content=下载，阅读！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJHmctib8wsjB1Y0etxU20nsCbR8rZ2fpibp2STmwH2YzicIsTe9oHRGB6XIMeBqNdIvxODicmzfeQibIw/132, createdBy=82211964557, createdName=清幽蓝燕yan, createdTime=Thu Jan 12 23:18:10 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=169790, encodeId=52e0169e9014, content=又增加了知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82722003086, createdName=于宝宝, createdTime=Thu Jan 12 09:33:22 CST 2017, time=2017-01-12, status=1, ipAttribution=)]
    2017-01-15 1e160a78m83(暂无匿称)

    学习啦，谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=170542, encodeId=ebeb1e0542d1, content=学习啦，谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/31/60fc0213ae09a3dbbba19993663ef4db.jpg, createdBy=33c31971480, createdName=1e160a78m83(暂无匿称), createdTime=Sun Jan 15 16:06:32 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=169936, encodeId=248e1699364a, content=下载，阅读！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJHmctib8wsjB1Y0etxU20nsCbR8rZ2fpibp2STmwH2YzicIsTe9oHRGB6XIMeBqNdIvxODicmzfeQibIw/132, createdBy=82211964557, createdName=清幽蓝燕yan, createdTime=Thu Jan 12 23:18:10 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=169790, encodeId=52e0169e9014, content=又增加了知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82722003086, createdName=于宝宝, createdTime=Thu Jan 12 09:33:22 CST 2017, time=2017-01-12, status=1, ipAttribution=)]
    2017-01-12 清幽蓝燕yan

    下载，阅读！

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=170542, encodeId=ebeb1e0542d1, content=学习啦，谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/31/60fc0213ae09a3dbbba19993663ef4db.jpg, createdBy=33c31971480, createdName=1e160a78m83(暂无匿称), createdTime=Sun Jan 15 16:06:32 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=169936, encodeId=248e1699364a, content=下载，阅读！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJHmctib8wsjB1Y0etxU20nsCbR8rZ2fpibp2STmwH2YzicIsTe9oHRGB6XIMeBqNdIvxODicmzfeQibIw/132, createdBy=82211964557, createdName=清幽蓝燕yan, createdTime=Thu Jan 12 23:18:10 CST 2017, time=2017-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=169790, encodeId=52e0169e9014, content=又增加了知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82722003086, createdName=于宝宝, createdTime=Thu Jan 12 09:33:22 CST 2017, time=2017-01-12, status=1, ipAttribution=)]
    2017-01-12 于宝宝

    又增加了知识

    0